Last reviewed · How we verify
Cimicifuga racemosa
At a glance
| Generic name | Cimicifuga racemosa |
|---|---|
| Also known as | Black Cohosh |
| Sponsor | Irmandade da Santa Casa de Misericordia de Sao Paulo |
| Drug class | Copper-containing Intrauterine Device [EPC] |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- The Benefits of Natural Medicine, Vitamin IV Therapy and Supplements: Maintaining Good Health Through Nature
- Assessing the Synergistic Effects of Black Cohosh, Soy Isoflavones, and SDG Lignans (Soloways TM) on Menopausal Symptoms (NA)
- A Pilot Pre-operative Window Trial of Black Cohosh in Women With Ductal Carcinoma in Situ (NA)
- EFFICACY OF ANSA (Experimental Drug) & CRAN MAX (Control Drug) SACHET (PHASE3)
- Comparative Study to Evaluate the Efficacy and Safety of the Fixed-dose Combination of Estradiol / Dydrogesterone in Perimenopausal Women (PHASE4)
- Effect of Menopause Relief EP-40 in Women With Menopausal Symptoms (PHASE2)
- Vascular Effect of CIMICIFUGA RACEMOSA (NA)
- Remifemin Preventing the Climacteric Symptoms in Breast Cancer (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Cimicifuga racemosa CI brief — competitive landscape report
- Cimicifuga racemosa updates RSS · CI watch RSS
- Irmandade da Santa Casa de Misericordia de Sao Paulo portfolio CI